Please assess the completion status of the following clinical trial:

Trial Title: Risk Stratified Sequential Treatment for CD20-positive PTLD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTLD with or without EBV association, confirmed after biopsy or resection of tumor~* Measurable disease of \> 2 cm in diameter and/or bone marrow involvement~* Patients having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or other or a combination of the organ transplantations mentioned~* Karnofsky scale \>50% or ECOG ≤ 3~* Reduction of immunosuppression with or without antiviral therapy~* A complete surgical extirpation of tumor was not performed~* A radiation therapy was not performed~* Effective contraception for women in childbearing age~* Patient's written informed consent and written consent for data collection~* Patients are \> 18 years (or ≥ 15 years with parental agreement )~Exclusion Criteria:~* Life expectancy less than 6 weeks~* Karnofsky-scale \<50% or ECOG ≥ 3~* Treatment with rituximab before~* Known allergic reactions against foreign proteins~* Concomitant diseases, which exclude the administration of therapy as outlined by the study protocol~* non-compensated heart failure~* Dilatative cardiomyopathy~* Myocardial infarction during the last 6 months~* Severe non-compensated hypertension~* Severe non-compensated diabetes mellitus~* Renal insufficiency (creatinine more than 3-fold of the upper normal value), not related to lymphoma~* Hepatic insufficiency with transaminase values greater than 3-fold of the normal values and/or bilirubin levels \>3.0 mg/dl, not related to lymphoma~* Clinical signs of cerebral dysfunction~* Women during the lactation period, pregnant or of childbearing potential not using a reliable contraceptive method~* Involvement of the central nervous system by the disease~* Severe psychiatric disease~* Known to be HIV positive~* Missing written informed consent of the patient

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
- B (Type: EXPERIMENTAL): All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.

Based on this trial design, predict the completion outcome and termination type (if applicable).